Amgen Vectibix Assistance Program May Balance Part B Pricing Pressures
Executive Summary
Amgen's pricing strategy for its colorectal cancer therapy Vectibix appears to balance the competing pricing pressures created by Medicare Part B's average sales price-based reimbursement methodology
You may also be interested in...
Avastin For Lung Cancer Will Be Free To Patients Who Beat The Average
Under a Genentech program that caps expenditures for Avastin, the oncologic will be free of charge to patients who continue using the therapy beyond the median duration of treatment for lung cancer
Avastin For Lung Cancer Will Be Free To Patients Who Beat The Average
Under a Genentech program that caps expenditures for Avastin, the oncologic will be free of charge to patients who continue using the therapy beyond the median duration of treatment for lung cancer
Amgen Vectibix Cap Cuts Patient Cost, But Will Payers Balk At High Price?
Amgen announced a program to limit patients' out-of-pocket cost for Vectibix, following FDA approval of panitumumab Sept. 27.